[Asia Economy Reporter Jang Hyowon] GeneOne Life Science announced on the 16th that the mechanism of action of GLS-1027 (Genuzolac), an oral small-molecule anti-inflammatory therapeutic under development, has been published in the international academic journal Translational Medicine Communications.
This journal is published by BMC, a sister journal of the global scientific publisher Springer Nature. The title of the paper is "Characterization of a small molecule modulator of inflammatory cytokine production," and the study was conducted as a collaborative research led by GeneOne Life Science's R&D group in partnership with the University of Pennsylvania in the United States and the University of Catania in Italy.
According to the company, the study investigated the effects of GLS-1027 on various immune cell types that mediate inflammation. The results confirmed that GLS-1027 suppresses cytokine production from immune cells and affects the maturation of key cell types involved in triggering inflammatory responses.
Furthermore, administration of GLS-1027 in the NOD (Non-obese diabetic) mouse model, a naturally occurring insulin-dependent diabetes model animal, significantly reduced blood levels of IL-17 and TNFα, which induce cytokine storms and inflammation. This was correlated with a decrease in the incidence of diabetes related to these factors.
GeneOne Life Science is developing GLS-1027, an immunomodulator that suppresses hyperimmune responses, as an oral therapeutic for COVID-19 infection. Currently, Phase 2 clinical trials are underway in South Korea, the United States, North Macedonia, and Bulgaria.
Dr. Joel Maslow, Chief Medical Officer of GeneOne Life Science, explained, "These research results reveal the mechanism of action of GLS-1027 for treating autoimmune and other inflammatory diseases, providing foundational data for expanding indications. It suggests the potential for developing GLS-1027 as an alternative to high-dose steroid therapies with high toxicity or anti-cytokine or antiviral monoclonal antibody therapies."
He added, "Currently, in collaboration with Cornell University, we are conducting canine clinical studies to develop GLS-1027 as a treatment for non-infectious uveitis, a disease that can cause blindness in humans, horses, and dogs. Additionally, preclinical studies are underway for acute ischemic nephropathy, Crohn's disease, and inflammatory bowel disease."
Park Younggeun, CEO of GeneOne Life Science, stated, "As the number of drugs failing or showing minimal efficacy in COVID-19 treatment continues to increase, and the urgent need for effective COVID-19 therapeutics grows, GLS-1027 has excellent potential as an efficient alternative not only for COVID-19 but also for various autoimmune disease treatments."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
